Zhitong Finance App News, Keji Pharmaceutical-B (02171.HK) announced that CT0596, a generic CAR-T cell product targeting BCMA, completed the first patient infusion in a phase I registered clinical trial in China to treat patients with recurrent/refractory multiple myeloma (R/R MM). The results of the CT0596 IIT study were presented on a poster at the 2026 European Society of Hematology (EHA) Annual Meeting.

Zhitongcaijing · 2d ago
Zhitong Finance App News, Keji Pharmaceutical-B (02171.HK) announced that CT0596, a general-purpose CAR-T cell product targeting BCMA, completed the first patient infusion in a phase I registered clinical trial in China to treat patients with recurrent/refractory multiple myeloma (R/R MM). The results of the CT0596 IIT study were presented on a poster at the 2026 European Society of Hematology (EHA) Annual Meeting.